gefitinib
FDA grants AstraZeneca immune drug orphan status
April 15, 2015Sales and Marketing AstraZeneca, FDA, Iressa, MEDI4736, MedImmune, NSCLC, US, gefitinib, non-small cell lung cancer, tremelimumab
The US Food and Drug Administration has granted orphan drug designation to AstraZeneca’s anti-CTLA-4 monoclonal antibody tremelimumab for the treatment …
Retrospective study backs Iressa use in oesophageal cancer
November 5, 2014Research and Development, Sales and Marketing AstraZeneca, Cancer, Cancer Oesophagus Gefitinib, Iressa, gefitinib, oncology
A group of oesophageal cancer patients can increase their survival by six months or more if treated with AstraZeneca’s Iressa, …
AZ and Pfizer support personalised medicine database
February 8, 2011Research and Development AZ, AstraZeneca, Cancer Research UK, Iressa, Pfizer, crizotinib, gefitinib, personalised medicine
AstraZeneca and Pfizer have teamed up with leading charity Cancer Research UK to help develop its stratified medicines programme. Stratified …
Latest content
Global coalition calls for stronger government action on COPD
September 18, 2026
Global health researchers call for more equitable partnerships
September 17, 2026
Liverpool launches £20m lab for infectious disease drug discovery
September 16, 2026
Circle Health Group expands into UK laboratory operations
September 15, 2026
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
September 14, 2026
